The European Medicines Agency (EMA) has updated its rules on declarations of interests for scientific committee members and experts.
The European Medicines Agency (EMA) has updated its rules on declarations of interests for scientific committee members and experts. The changes are designed to strengthen the agency’s policy by restricting involvement of experts in the scientific assessment of medicines if they plan to take up a job in the pharmaceutical industry.
“The effective management of conflicts of interests is key to ensuring the independence and integrity of the Agency’s scientific recommendations,” says Noël Wathion, EMA’s Chief Policy Adviser. “EMA continually reviews its policy to ensure that the rules are fit for purpose.”
EMA considers that employment in a pharmaceutical company is incompatible with an involvement in the agency’s activities. When a member of a scientific committee or working party informs EMA that he/she intends to work for a pharmaceutical company, the agency will immediately restrict the member from any participation in the evaluation of medicines. If necessary, the Agency will also verify whether the integrity of any ongoing or past scientific reviews in which that person was involved could have been compromised.
EMA’s declaration of interest policy aims for a balanced approach by restricting the involvement of experts with possible conflicts of interests, while maintaining EMA’s ability to access the best available expertise. The updates also include a revised guide on how to complete the Agency’s declaration of interest form.
In March 2014, the EMA management board endorsed a major revision of EMA’s policy on handling declarations of interest for scientific committee members and experts. The revision took into account input from stakeholders at the Agency’s September 2013 public workshop 'Best expertise vs conflicts of interests: striking the right balance'. It entered into force on January 30th.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.